Abstract Androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI) ± docetaxel represent the standard of care in patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, some patients still have early progression (EP). EMETPRO is a multicentric, retrospective registry of patients with EP mHSPC. Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start.
Curating Slow Fashion brands' communications, social media, digital strategy & PR, route to market. Retail tours. Also more #SoMe & #FashTech over @MosaicSocial
Get in touch with Veronica
Contact Veronica, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack